Results 221 to 230 of about 165,965 (304)

GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives. [PDF]

Nutrients
Suastika LOS, Bando YK, Hoshino K, Koitabashi N, Saito Y, Yuasa S, Nakamura K.   +6 more
europepmc   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Reply: Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F.   +3 more
europepmc   +1 more source

Under‐ and overdosing insulin in the hospital: A retrospective cohort study of dose deviation and patient outcomes

Diabetic Medicine, EarlyView.
Abstract Aims Glycaemic abnormalities during hospitalization are common and linked to morbidity and mortality, yet little is known about how deviations from guideline‐recommended insulin dosing affect outcomes. The aim of this study is to examine whether deviation from an expected insulin dose in non‐critically ill hospitalized adults with type 2 ...
Hussein Zaitoon, Sher Matsri, Shira Nagler, Matteo M. Lalovich, Ralph A. DeFronzo, Eugene Feigin   +5 more
wiley   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. [PDF]

J Cosmet Dermatol
Argobi Y, Jadaan NS, Alshalhoob HB, Alyousef MS, Alotaibi GM, Alwesaibie HS, Alshehri ISM.   +6 more
europepmc   +1 more source

Importance of Hypercortisolism in BP Control, Cardiovascular Risk and in Patients With Difficult‐to‐Control Hypertension: An Overview for Primary Care Physicians

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension remains one of the most prevalent and consequential modifiable cardiovascular risk factors worldwide, affecting approximately 1.28 billion adults globally and nearly half of the United States population. Despite the availability of effective therapies, optimal blood pressure control is achieved in fewer than one in four ...
Matthew A. Cavender
wiley   +1 more source

Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trials. [PDF]

Neurol Sci
Mendonça MF, Interaminense AC, do R Barros GST, Rabelo LA, de Oliveira PG, Sales RF, de C Lyra AMV, de S E Silva HR.   +7 more
europepmc   +1 more source

How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target‐organ damage.
Omar Al Dhaybi, Deepak L. Bhatt
wiley   +1 more source